Showing 1491-1500 of 1616 results for "".
- Blue Light Glasses: Helpful or Just Hype?https://modernod.com/news/blue-light-glasses-helpful-or-just-hype/2477179/Erin Lynn Sattler started worrying when her vision became blurry while using the computer, but her eye doctor said her eyes were fine. Then she got a new computer at work, with a much brighter screen, and her eyes and head started hurting. She’d heard of blue light glasses and did some
- Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of DR, AMD, and Glaucomahttps://modernod.com/news/eyenuk-secures-the-first-european-union-mdr-certification-for-autonomous-ai-detection-of-diabetic-retinopathy-amd-and-glaucoma/2481377/Eyenuk has been approved to market its EyeArt AI eye screening system in the European Union for the new uses of detecting age-related macular degeneration (AMD) and glaucomatous optic nerve damage. The EyeArt AI system (version 3.0) has been granted a new European Commiss
- Samsung Bioepis to Regain European Commercial Rights for Ophthalmology Biosimilars from Biogenhttps://modernod.com/news/samsung-bioepis-to-regain-european-commercial-rights-for-ophthalmology-biosimilars-from-biogen/2484299/Samsung Bioepis has entered into an Asset Purchase Agreement (APA) with Biogen concerning the transfer of two ophthalmology assets: Byooviz (ranibizumab) and Opuviz (aflibercept)—both biosimilars referencing leading treatments for retinal disea
- OneSight EssilorLuxottica Foundation and Vision To Learn Extend Partnership to Expand Vision Care for Children Nationwidehttps://modernod.com/news/onesight-essilorluxottica-foundation-and-vision-to-learn-extend-partnership-to-expand-vision-care-for-children-nationwide/2484209/The OneSight EssilorLuxottica Foundation and Vision To Learn announced a 2-year extension of their 8-year partnership dedicated to providing vision care services to children in need—helping them see clearly and reach their full potential in school and be
- Topcon Healthcare Launches IDHea to Advance Digital Research in Eye Care and Oculomicshttps://modernod.com/news/topcon-healthcare-launches-idhea-to-advance-digital-research-in-eye-care-and-oculomics/2484202/Topcon Healthcare announced the launch of IDHea Inc., the Institute for Digital Health, a new company dedicated to transforming clinical research in eye care and the emerging field of oculomics—the study of ocular biomarkers that reflect systemic health.
- Virtual Vision Health Expands Virtual Eye Platform with New Diagnostic Modules and Multi-Exam Integrationhttps://modernod.com/news/virtual-vision-health-expands-virtual-eye-platform-with-new-diagnostic-modules-and-multi-exam-integration/2484191/Virtual Vision Health announced a series of upgrades to its Virtual Eye platform—a VR vision testing system designed to deliver immersive, data-driven visual field, progression analysis, and functional eye assessments.
- Konan Medical Receives CE Marking for ObjectiveFIELD Analyzer (OFA)https://modernod.com/news/konan-medical-receives-ce-marking-for-objectivefield-analyzer-ofa/2484170/Konan Medical USA announced that its objectiveFIELD Analyzer (OFA) has received CE Marking under the European Medical Device Regulation (MDR). The CE Mark enables Konan Medical to offer its next-generation perimetry solution to healthcare providers throug
- Oculus Smartfield Perimeter Launches Aboard the International Space Station to Support Vision Researchhttps://modernod.com/news/oculus-smartfield-perimeter-launches-aboard-the-international-space-station-to-support-vision-research/2484168/Oculus announced that its Smartfield perimeter has successfully launched aboard the International Space Station (ISS) to support research on Spaceflight Associated Neuro-ocular Syndrome (SANS)—a condition known to affect astronauts’ vision during l
- Regenxbio Completes Enrollment in ATMOSPHERE and ASCENT Trials of Sura-Vec Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-enrollment-in-atmosphere-and-ascent-trials-of-sura-vec-gene-therapy-for-wet-amd/2484155/Regenxbio announced the completion of enrollment in its two pivotal phase 3 studies—ATMOSPHERE and ASCENT—evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314), an investigational one-time gene therapy for wet age-related macular degeneration (
- SightGlass Vision: New 18-Month Data Reinforce DOT Lens Effectivenesshttps://modernod.com/news/sightglass-vision-new-18-month-data-reinforce-dot-lens-effectiveness/2484152/New 18-month clinical data presented by SightGlass Vision at the American Academy of Optometry 2025 annual meeting show that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly 4 times th